Brazil hospital covid-19 patient Brazil

COVID outpatients don't benefit from hydroxychloroquine, lopinavir-ritonavir

Reading now: 727
www.cidrap.umn.edu

A randomized, controlled trial of 685 adult COVID-19 outpatients in Brazil finds that neither the antimalaria drug hydroxychloroquine nor the antiviral drugs lopinavir-ritonavir significantly lowered rates of coronavirus–related hospitalizations when given soon after symptom onset.In the study, published today in JAMA Network Open, researchers from the Cardresearch-Cardiologica Assistencial e de Pesquisa enrolled COVID-19 outpatients with recent symptom onset in 10 cities in Brazil from Jun 2 to Oct 9, 2020.

The trial was stopped after the interim analysis owing to treatment futility. The study was part of the TOGETHER Trial to evaluate the effectiveness of repurposed therapies in high-risk, nonhospitalized, adult COVID-19 patients.No

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA